W E Meijer1, M L Bouvy, E R Heerdink, J Urquhart, H G Leufkens. 1. Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands. W.E.E.Meijer@pharm.uu.nl
Abstract
BACKGROUND: In previous research, lapses in dosing of paroxetine or sertraline were associated with significantly more discontinuation symptoms and deterioration of depressive symptomatology compared with fluoxetine. AIMS: To evaluate dosing lapses in patients chronically treated with selective serotonin reuptake inhibitors (SSRIs) in uncontrolled circumstances. METHOD: In a prospective observational study we evaluated compliance data in chronic users of SSRIs using electronic drug exposure monitors. RESULTS: During a 3-month follow-up we found that 50/69 (72.5%) patients missed at least one dosing day and 20/69 (29.0%) missed two or more consecutive days. CONCLUSIONS: About 30% of patients treated with short-acting SSRIs had dosing lapses of 2 or more days, which, as described in prior studies, is long enough to result in clinically relevant deterioration of mental status.
BACKGROUND: In previous research, lapses in dosing of paroxetine or sertraline were associated with significantly more discontinuation symptoms and deterioration of depressive symptomatology compared with fluoxetine. AIMS: To evaluate dosing lapses in patients chronically treated with selective serotonin reuptake inhibitors (SSRIs) in uncontrolled circumstances. METHOD: In a prospective observational study we evaluated compliance data in chronic users of SSRIs using electronic drug exposure monitors. RESULTS: During a 3-month follow-up we found that 50/69 (72.5%) patients missed at least one dosing day and 20/69 (29.0%) missed two or more consecutive days. CONCLUSIONS: About 30% of patients treated with short-acting SSRIs had dosing lapses of 2 or more days, which, as described in prior studies, is long enough to result in clinically relevant deterioration of mental status.
Authors: Yan Feng; Bruce G Pollock; Robert E Ferrell; Mark A Kimak; Charles F Reynolds; Robert R Bies Journal: Br J Clin Pharmacol Date: 2006-05 Impact factor: 4.335
Authors: Yan Feng; Marc R Gastonguay; Bruce G Pollock; Ellen Frank; Gail H Kepple; Robert R Bies Journal: Neuropsychiatr Dis Treat Date: 2011-03-17 Impact factor: 2.570
Authors: E C G van Geffen; S W van der Wal; R van Hulten; M C H de Groot; A C G Egberts; E R Heerdink Journal: Eur J Clin Pharmacol Date: 2007-09-15 Impact factor: 2.953